Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
McPherson
M E
ME
Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA. Marianne.McPherson@choa.org
Hutcherson
D
D
Olson
E
E
Haight
A E
AE
Horan
J
J
Chiang
K-Y
KY
D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000628:therapy*; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D002066:Busulfan / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D046528:Chimerism / Q000187:drug effects; D016903:Drug Monitoring / Q000009:adverse effects; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D008297:Male; D019653:Myeloablative Agonists / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012189:Retrospective Studies; D035781:Siblings; D016019:Survival Analysis; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000009:adverse effects
D019653:Myeloablative Agonists; D002066:Busulfan